Critical Pharmacodynamic Warning

chloramphenicol affects the 2C19 metabolic pathway.

When patients take chloramphenicol concurrently with drugs metabolized by 2C19, the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.

Clinical Impact: As a strong inhibitor , chloramphenicol can alter the metabolism of substrate drugs, requiring careful monitoring and potential dose adjustments.

Clinical Overview for chloramphenicol

This page outlines known interaction pathways involving chloramphenicol, focusing primarily on its profile as a Strong inhibitor affecting the 2C19 pathway.

Enzyme Interaction Profile

chloramphenicol demonstrates strong inhibitor potency against 2C19. Clinical significance of this interaction requires further evaluation.

Inhibitor

A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.

Clinical Example: chloramphenicol affects 2C19

Inducer

A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.

Known Inducers: efavirenz
Interaction Details
Drug Name chloramphenicol
Affected Enzyme 2C19
Inhibitor Strength Strong inhibitor Unknown
Inducers efavirenz
Inhibitors fluvoxamine
Clinical Recommendations

Consult primary literature for guidance.

Monitoring Parameters:
  • Therapeutic drug levels
  • Adverse effect monitoring
  • Clinical response assessment
Dose Considerations:
  • Consider dose reduction
  • Evaluate alternative therapies
  • Adjust based on response
Quick Facts
Interaction ID
5040
Primary Pathway
2C19
Interaction Type
Enzyme Inhibition
Clinical Phase
Unknown
Clinical Significance

Clinical significance requires further evaluation.

Information Sources
  • FDA Drug Interaction Database
  • Clinical Pharmacology Guidelines
  • Pharmaceutical Labeling Information
  • Published Clinical Studies
Last updated: June 12, 2026
Back Return to Database